[Click eStock] "FromBio, Promising Cell Therapy for Hair Loss Treatment"

FS Research analyzed on the 3rd that it is time to pay attention to FromBio's new business in the bio sector.

Hwang Se-hwan, a researcher at FS Research, explained, "FromBio has been accelerating its bio business since last May when it registered a patent for differentiating adipose-derived stem cells into dermal papilla cells."

He continued, "Although it is still in the preclinical stage, hair growth effects were confirmed by injecting differentiated dermal papilla cells into normal mice," adding, "Since early this year, efficacy and safety tests have begun, and preclinical results are expected in the second half of the year."

He emphasized, "The global hair loss market is estimated to be worth 27 trillion won," and added, "There is no definite treatment method other than hair transplantation." Furthermore, he explained, "Because the market size is large and there is no proper treatment, just being involved in hair loss-related business has increased interest in FromBio."

Researcher Hwang analyzed, "Considering the confirmation of hair growth effects in preclinical trials and the expected release of preclinical results this year, the current stock price presents a point worth paying attention to."

This content was produced with the assistance of AI translation services.